301 related articles for article (PubMed ID: 37081982)
1. Patient-derived xenografts or organoids in the discovery of traditional and self-assembled drug for tumor immunotherapy.
Zhang W; Zheng X
Front Oncol; 2023; 13():1122322. PubMed ID: 37081982
[TBL] [Abstract][Full Text] [Related]
2. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
Hamdan F; Ylösmäki E; Chiaro J; Giannoula Y; Long M; Fusciello M; Feola S; Martins B; Feodoroff M; Antignani G; Russo S; Kari O; Lee M; Järvinen P; Nisen H; Kreutzman A; Leusen J; Mustjoki S; McWilliams TG; Grönholm M; Cerullo V
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362830
[TBL] [Abstract][Full Text] [Related]
3. Construction of
Takahashi N; Higa A; Hiyama G; Tamura H; Hoshi H; Dobashi Y; Katahira K; Ishihara H; Takagi K; Goda K; Okabe N; Muto S; Suzuki H; Shimomura K; Watanabe S; Takagi M
Oncol Lett; 2021 May; 21(5):406. PubMed ID: 33841567
[TBL] [Abstract][Full Text] [Related]
4. Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy.
Qu J; Kalyani FS; Liu L; Cheng T; Chen L
Cancer Commun (Lond); 2021 Dec; 41(12):1331-1353. PubMed ID: 34713636
[TBL] [Abstract][Full Text] [Related]
5. Application of organoids in precision immunotherapy of lung cancer (Review).
Tian H; Ren J; Mou R; Jia Y
Oncol Lett; 2023 Nov; 26(5):484. PubMed ID: 37818130
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models.
Chew NJ; Lim Kam Sian TCC; Nguyen EV; Shin SY; Yang J; Hui MN; Deng N; McLean CA; Welm AL; Lim E; Gregory P; Nottle T; Lang T; Vereker M; Richardson G; Kerr G; Micati D; Jardé T; Abud HE; Lee RS; Swarbrick A; Daly RJ
Breast Cancer Res; 2021 Aug; 23(1):82. PubMed ID: 34344433
[TBL] [Abstract][Full Text] [Related]
7. Advances of Patient-Derived Organoids in Personalized Radiotherapy.
Wang Y; Li Y; Sheng Z; Deng W; Yuan H; Wang S; Liu Y
Front Oncol; 2022; 12():888416. PubMed ID: 35574360
[TBL] [Abstract][Full Text] [Related]
8. Bladder Cancer Patient-derived Organoids and Avatars for Personalized Cancer Discovery.
Kim YS; Hsieh AC; Lam HM
Eur Urol Focus; 2022 May; 8(3):657-659. PubMed ID: 35915037
[TBL] [Abstract][Full Text] [Related]
9. Screening of an individualized treatment strategy for an advanced gallbladder cancer using patient-derived tumor xenograft and organoid models.
Tan D; An J; Gong M; Wang H; Li H; Meng H; Zhang C; Zhao Y; Ge X; Shi C
Front Oncol; 2022; 12():1043479. PubMed ID: 36591461
[TBL] [Abstract][Full Text] [Related]
10. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
11. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
12. Translational and Clinical Relevance of PDX-Derived Organoid Models in Oncology Drug Discovery and Development.
Kumari R; Xu X; Li HQ
Curr Protoc; 2022 Jul; 2(7):e431. PubMed ID: 35789132
[TBL] [Abstract][Full Text] [Related]
13. Organoid Models for Precision Cancer Immunotherapy.
Sun CP; Lan HR; Fang XL; Yang XY; Jin KT
Front Immunol; 2022; 13():770465. PubMed ID: 35450073
[TBL] [Abstract][Full Text] [Related]
14. Applications of patient-derived tumor xenograft models and tumor organoids.
Yoshida GJ
J Hematol Oncol; 2020 Jan; 13(1):4. PubMed ID: 31910904
[TBL] [Abstract][Full Text] [Related]
15. Establishment and Analysis of Three-Dimensional (3D) Organoids Derived from Patient Prostate Cancer Bone Metastasis Specimens and their Xenografts.
Lee S; Burner DN; Mendoza TR; Muldong MT; Arreola C; Wu CN; Cacalano NA; Kulidjian AA; Kane CJ; Jamieson CAM
J Vis Exp; 2020 Feb; (156):. PubMed ID: 32065165
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option.
Ren Y; Miao JM; Wang YY; Fan Z; Kong XB; Yang L; Cheng G
Front Immunol; 2022; 13():961796. PubMed ID: 35911673
[TBL] [Abstract][Full Text] [Related]
18. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
[TBL] [Abstract][Full Text] [Related]
19. Preclinical tumor organoid models in personalized cancer therapy: Not everyone fits the mold.
Hu LF; Yang X; Lan HR; Fang XL; Chen XY; Jin KT
Exp Cell Res; 2021 Nov; 408(2):112858. PubMed ID: 34600901
[TBL] [Abstract][Full Text] [Related]
20. Directing Hypoxic Tumor Microenvironment and HIF to Illuminate Cancer Immunotherapy's Existing Prospects and Challenges in Drug Targets.
Ray SK; Mukherjee S
Curr Drug Targets; 2022; 23(5):471-485. PubMed ID: 35021970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
